Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is an extended-spectrum penicillin antibiotic combined with a beta-lactamase inhibitor. It is active against many Gram-positive, Gram-negative (including *Pseudomonas aeruginosa*), and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Empirical treatment for febrile neutropenia
## Adult Dosing
* **Intravenous (IV) Infusion:**
* Common dose: 3.375 g (3 g piperacillin/0.375 g tazobactam) every 6 hours.
* Severe infections: 4.5 g (4 g piperacillin/0.5 g tazobactam) every 6 or 8 hours.
* **Maximum dose:** 18 g (16 g piperacillin/2 g tazobactam) per day.
* Duration of therapy is typically 7-14 days, depending on the infection and clinical response.
* Infusion should be over at least 30 minutes.
## Pediatric Dosing
* **Intravenous (IV) Infusion:**
* **1 month to < 12 years or weight < 40 kg:** Dosing is based on piperacillin component.
* Mild to moderate infections: 24.375 mg/kg (21.75 mg piperacillin/2.625 mg tazobactam) every 8 hours.
* Severe infections or *Pseudomonas aeruginosa* infections: 32.5 mg/kg (29.25 mg piperacillin/3.25 mg tazobactam) every 6 hours.
* **≥ 12 years or weight ≥ 40 kg:** Use adult dosing.
* **Neonates (< 1 month):** Dosing is complex and should follow specific guidelines due to immature renal and hepatic function. Typically, 2.25 g (2 g piperacillin/0.25 g tazobactam) every 8 hours for term infants, and every 12 hours for preterm infants, but this requires careful consideration and may vary.
* Infusion should be over at least 30 minutes.
## Dose Adjustments
* **Renal Impairment (CrCl < 20 mL/min):**
* Doses should be reduced, and/or intervals extended. Consult product labeling or institutional guidelines. A common regimen is 2.25 g (2 g piperacillin/0.25 g tazobactam) every 8 hours, or 3.375 g every 12 hours.
* **Hepatic Impairment:** No specific dose adjustment is usually recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to piperacillin, tazobactam, other penicillins, or beta-lactamase inhibitors.
* History of immediate or severe allergic reaction to beta-lactam antibiotics.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, pruritus, headache, insomnia, hypokalemia.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (especially with high doses or renal impairment), interstitial nephritis, hematologic changes (neutropenia, thrombocytopenia, eosinophilia, leukopenia), hepatotoxicity.
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** Piperacillin may decrease the efficacy of warfarin; monitor INR closely.
* **Aminoglycosides:** Concurrent use may be synergistic but also increases the risk of nephrotoxicity. Do not mix in the same IV line.
## Monitoring
* **Renal function:** Baseline and periodic monitoring, especially in patients with pre-existing renal disease or those receiving nephrotoxic agents.
* **Electrolytes:** Monitor potassium levels, particularly in patients receiving diuretics or those with hypokalemia risk.
* **Liver function tests:** Baseline and periodic monitoring.
* **Signs and symptoms of infection:** Clinical response, fever, WBC count.
* **Signs of hypersensitivity reactions:** Rash, pruritus, angioedema, bronchospasm.
* **Stool for *C. difficile*:** If diarrhea develops.
## Clinical Pearls
* The reconstitution and dilution of piperacillin/tazobactam require specific volumes of diluent to achieve the desired concentrations.
* When reconstituted, the drug is a powder that is then further diluted for IV infusion.
* Ensure adequate hydration to minimize the risk of crystalluria.
* In patients with severe renal impairment, monitor for signs of neurotoxicity.
* For empirical treatment of febrile neutropenia, piperacillin/tazobactam is often used in combination with an aminoglycoside or fluoroquinolone, depending on local resistance patterns and patient risk factors.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and institutional guidelines before administering any medication.
